Sermorelin vs MK-677 (Ibutamoren): How They Differ

Sermorelin and MK-677 (ibutamoren) get compared constantly because they're sold to the same audience with the same pitch: raise your own growth hormone without injecting growth hormone itself. That shared goal hides how different the two actually are. One is a peptide you inject; the other is a pill that hits a completely different receptor. One is compounded by pharmacies; the other never made it through clinical development and is sold as a research chemical. And their side-effect profiles are not the same. If you're choosing between them — especially for sleep, recovery, or healthy-aging reasons rather than bodybuilding — those differences matter more than the marketing suggests.

The headline difference: peptide injection vs oral research chemical

Sermorelin is a peptide — a GHRH analog you inject. It is GHRH(1-29), the first 29 amino acids of growth-hormone-releasing hormone, the shortest fragment that keeps the full GH-releasing activity of the natural hormone¹. It binds the GHRH receptor on the pituitary — the same receptor your own hypothalamic GHRH uses — and is given by subcutaneous injection because, like most peptides, it's broken down in the gut. It's short-acting: it nudges a pulse of growth hormone and clears quickly.

MK-677 (ibutamoren) is not a peptide at all. It's a small, orally active, non-peptide molecule that mimics the stomach hormone ghrelin at the growth hormone secretagogue receptor (GHS-R)² — the receptor identified in the pituitary and hypothalamus in 1996³ whose natural ligand, ghrelin, was discovered in 1999⁴. Because it's not a peptide, it survives digestion, so it works as a once-daily oral dose and has a long enough action to keep IGF-1 elevated around the clock. In published trials it reliably raised growth hormone and IGF-1 in people⁵.

So the most basic split is: sermorelin is an injectable GHRH peptide; MK-677 is an oral ghrelin-receptor drug. Same destination — more growth hormone — by two unrelated routes and two different receptors. We cover the GHRH side of that axis in depth in our pillar guide to sermorelin's evidence.

Regulatory status: read this before you buy either

This is where most casual comparisons go wrong, because neither compound is a normal FDA-approved medicine — but they're un-approved in different ways.

Sermorelin once had an FDA approval — the brand Geref — which was discontinued for commercial, not safety, reasons. Today it has no active approval, so every US dose is compounded by a pharmacy and prescribed off-label. That's legal and routine, and it means a prescriber and a licensed compounding pharmacy are in the loop.

MK-677 has never been an FDA-approved drug at all. Despite an extensive clinical program through the late 1990s and 2000s — for the somatopause, frailty, hip-fracture recovery, and even Alzheimer's — it did not earn approval for any indication, and development was ultimately halted⁶. A large randomized trial in Alzheimer's disease, for example, found no clinical benefit on disease progression⁷, and the hip-fracture program, while it improved some functional measures, did not lead to a product⁸. Today MK-677 circulates as a "research chemical" sold for laboratory use and not for human consumption, and it appears on the World Anti-Doping Agency's prohibited list as a growth-hormone secretagogue. Buying it usually means an unregulated vial or capsule with no guarantee of identity, dose accuracy, or purity — a hazard separate from the molecule itself.

The honest framing: sermorelin is compounded-and-off-label (a tier below an approved drug, but with pharmacy oversight); MK-677 is an investigational compound that failed to reach approval and now trades grey-market. That is not a small distinction.

What the human evidence actually shows

Both compounds raise GH and IGF-1 — that part is real and repeatedly demonstrated. The gap is between "raises a hormone marker" and "proven to improve how people look, feel, sleep, or function," and on that count both fall short of the marketing.

Sermorelin's human evidence is old and marker-based. The most-cited supporting study gave GHRH(1-29) as single nightly injections to healthy elderly men and showed it raised growth hormone and IGF-1¹ — a genuine finding, but a small, short study of blood markers, not of body composition or longevity. Its other solid human role is diagnostic: GHRH(1-29) was used as a provocative test of pituitary GH reserve⁹. No modern, large outcome trial shows sermorelin improves body composition or reverses aging. We hold that line in is sermorelin really anti-aging?.

MK-677 actually has a stronger trial record — and it's instructive. The standout study is a randomized, double-blind, placebo-controlled trial in healthy older adults that gave oral MK-677 for a full year. It raised growth hormone and IGF-1 to levels seen in young adults and produced a real increase in fat-free (lean) mass — but, critically, it did not improve strength or function, and the lean-mass gain was accompanied by side effects⁵. That trial is the most honest thing in this whole comparison: it proves an oral secretagogue can move body composition, and it simultaneously shows that moving the number didn't translate into the performance or functional benefit people are buying it for. MK-677 also reliably raised IGF-1 in other populations, such as hemodialysis patients¹⁰, and reversed diet-induced protein catabolism in a short metabolic study¹¹ — again, mechanism-confirming, not proof of the longevity or physique outcomes it's sold under.

So the scoreboard: sermorelin has decades of use but only short marker studies; MK-677 has more and better trials, including a year-long RCT, but those trials mostly show it raises markers and lean mass without the functional payoff — and it still never won approval.

Side effects: this is the real dividing line

Because both compounds raise the GH/IGF-1 axis, they share the same class cautions: fluid retention, joint aches, carpal-tunnel-type symptoms, and — most importantly — a tendency to raise blood glucose and insulin resistance. A systematic review of growth hormone in healthy older adults found GH significantly increased soft-tissue edema, arthralgias, carpal tunnel syndrome, and impaired fasting glucose versus placebo¹². That's the shared backdrop.

But MK-677 carries extra baggage that sermorelin generally doesn't, and it comes straight from the ghrelin receptor it activates. In the year-long older-adult trial, MK-677 was associated with increased appetite, fluid retention/edema, and — the most clinically important finding — a rise in fasting blood glucose and a fall in insulin sensitivity, signaling worsened glucose handling⁵. Reviews of the secretagogue class echo these: the ghrelin-mimetic mechanism predictably drives hunger, water retention, and the lethargy and "puffiness" many users report, alongside the glucose effect¹³. Because MK-677 keeps IGF-1 elevated continuously (rather than in a short pulse like injected sermorelin), there's a plausible argument that its metabolic effects are harder to escape between doses — though no head-to-head trial has tested that directly.

For a sleep, recovery, and healthy-aging reader specifically, the appetite spike, edema, lethargy, and especially the rise in blood sugar are the side effects to weigh most heavily — they're the ones most likely to undercut the very goals (feeling rested, recovering well, aging metabolically healthy) that draw people to this category in the first place. Anyone with prediabetes, diabetes, or metabolic risk should treat MK-677's glucose effect as the headline caution, not the puffy hands.

The IGF-1/cancer caution applies to both

Neither compound should be treated as a casual supplement, because chronically raising IGF-1 is not a neutral act. Large pooled analyses of prospective cohorts link higher circulating IGF-1 to a modestly increased risk of certain cancers — an epidemiological association with naturally varying IGF-1, not proof that a few months of a secretagogue causes cancer, but the mechanistic reason active or recent malignancy is treated as a contraindication for GH-axis therapy. We unpack that question for the GHRH side in does sermorelin cause cancer?. It applies in principle to MK-677 too — arguably more so, given how durably it elevates IGF-1.

Which fits the sleep, recovery & healthy-aging lane

If your interest is sleep quality, recovery, and metabolically healthy aging — not maximizing lean-mass numbers — the comparison tilts toward the more conservative option. Sermorelin's short, pulsatile action and pharmacy oversight make it the more measured choice for that lane, and bedtime dosing aligns with the body's natural overnight GH pulse (we cover that in the best time to take sermorelin). MK-677's continuous IGF-1 elevation, appetite stimulation, fluid retention, and glucose effects make it a poor fit for a healthy-aging goal even where it "works" on paper — the side effects run counter to the outcome. For the related GH peptides people also weigh against sermorelin, see sermorelin vs ipamorelin and sermorelin vs CJC-1295.

The bottom line

Sermorelin and MK-677 both raise growth hormone, but almost everything else about them differs. Sermorelin is an injectable, short-acting GHRH peptide, compounded and prescribed off-label with pharmacy oversight; its human evidence is old and marker-based. MK-677 is an oral, long-acting ghrelin-receptor drug that never gained FDA approval and now trades as a research chemical; it has better trials — including a year-long RCT — but those trials show it raises markers and lean mass without functional benefit, while bringing appetite spikes, fluid retention, lethargy, and a meaningful rise in blood glucose and insulin resistance⁵. For a sleep, recovery, and healthy-aging goal, that side-effect profile is the deciding factor. If you're comparing compounded sermorelin providers on price and oversight, we rank them honestly in our guide to the best sermorelin providers.